유럽의 생물제제 시장 예측(-2031년) - 지역별 분석(제품별, 용도별, 원료별, 제조 방법별)

The Europe biologics market was valued at US$ 1,15,057.6 million in 2023 and is expected to reach US$ 4,15,468.4 million by 2031; it is estimated to register a CAGR of 17.4% from 2023 to 2031.

Preference for Outsourcing Manufacturing Operations Drives Europe Biologics Market

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Europe Biologics Market Overview

The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.

Europe Biologics Market Revenue and Forecast to 2031 (US$ Million)

Europe Biologics Market Segmentation

The Europe biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macroeconomic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country-level data:

4. Europe Biologics Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Increasing Prevalence of Chronic Diseases
  • 4.1.2 Preference for Outsourcing Manufacturing Operations
• 4.2 Market Restraints
  • 4.2.1 High Cost of Biologics
• 4.3 Market Opportunities
  • 4.3.1 Gene and Cell Therapy Advancements in Biologics
• 4.4 Future Trends
  • 4.4.1 Strategic Initiatives by Companies
• 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Europe Analysis

• 5.1 Europe Biologics Market Revenue (US$ Million), 2021-2031
• 5.2 Europe Biologics Market Forecast Analysis

6. Europe Biologics Market Analysis - by Product

• 6.1 Monoclonal Antibodies
  • 6.1.1 Overview
  • 6.1.2 Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.2 Vaccine
  • 6.2.1 Overview
  • 6.2.2 Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.3 Recombinant Hormones/Proteins
  • 6.3.1 Overview
  • 6.3.2 Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.4 Cell and Gene Therapy
  • 6.4.1 Overview
  • 6.4.2 Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 6.5 Others
  • 6.5.1 Overview
  • 6.5.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Biologics Market Analysis - by Application

• 7.1 Cancer
  • 7.1.1 Overview
  • 7.1.2 Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.2 Infectious Diseases
  • 7.2.1 Overview
  • 7.2.2 Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.3 Autoimmune Diseases
  • 7.3.1 Overview
  • 7.3.2 Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 7.4 Others
  • 7.4.1 Overview
  • 7.4.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Biologics Market Analysis - by Source

• 8.1 Mammalian
  • 8.1.1 Overview
  • 8.1.2 Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 8.2 Microbial
  • 8.2.1 Overview
  • 8.2.2 Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Biologics Market Analysis - by Manufacturing

• 9.1 Outsourced
  • 9.1.1 Overview
  • 9.1.2 Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
• 9.2 In-house
  • 9.2.1 Overview
  • 9.2.2 In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Biologics Market - Country Analysis

• 10.1 Europe
  • 10.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 Germany: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.2.1 Germany: Europe Biologics Market Share - by Product
      • 10.1.1.2.2 Germany: Europe Biologics Market Share - by Application
      • 10.1.1.2.3 Germany: Europe Biologics Market Share - by Source
      • 10.1.1.2.4 Germany: Europe Biologics Market Share - by Manufacturing
    • 10.1.1.3 United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.3.1 United Kingdom: Europe Biologics Market Share - by Product
      • 10.1.1.3.2 United Kingdom: Europe Biologics Market Share - by Application
      • 10.1.1.3.3 United Kingdom: Europe Biologics Market Share - by Source
      • 10.1.1.3.4 United Kingdom: Europe Biologics Market Share - by Manufacturing
    • 10.1.1.4 Italy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.4.1 Italy: Europe Biologics Market Share - by Product
      • 10.1.1.4.2 Italy: Europe Biologics Market Share - by Application
      • 10.1.1.4.3 Italy: Europe Biologics Market Share - by Source
      • 10.1.1.4.4 Italy: Europe Biologics Market Share - by Manufacturing
    • 10.1.1.5 France: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.5.1 France: Europe Biologics Market Share - by Product
      • 10.1.1.5.2 France: Europe Biologics Market Share - by Application
      • 10.1.1.5.3 France: Europe Biologics Market Share - by Source
      • 10.1.1.5.4 France: Europe Biologics Market Share - by Manufacturing
    • 10.1.1.6 Spain: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.6.1 Spain: Europe Biologics Market Share - by Product
      • 10.1.1.6.2 Spain: Europe Biologics Market Share - by Application
      • 10.1.1.6.3 Spain: Europe Biologics Market Share - by Source
      • 10.1.1.6.4 Spain: Europe Biologics Market Share - by Manufacturing
    • 10.1.1.7 Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.1.1.7.1 Rest of Europe: Europe Biologics Market Share - by Product
      • 10.1.1.7.2 Rest of Europe: Europe Biologics Market Share - by Application
      • 10.1.1.7.3 Rest of Europe: Europe Biologics Market Share - by Source
      • 10.1.1.7.4 Rest of Europe: Europe Biologics Market Share - by Manufacturing

11. Industry Landscape

• 11.1 Overview
• 11.2 Market Initiative
• 11.3 Partnerships and Collaborations
• 11.4 Other Developments

12. Company Profiles

• 12.1 AbbVie Inc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Pfizer Inc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Samsung Biologics Co Ltd
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 ADMA Biologics, Inc.
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 WuXi Biologics Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Catalent Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 AGC Biologics AS
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 AstraZeneca Plc
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 Amgen Inc
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 Nitto Avecia
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments
• 12.11 Quality Assistance s.a.
  • 12.11.1 Key Facts
  • 12.11.2 Business Description
  • 12.11.3 Products and Services
  • 12.11.4 Financial Overview
  • 12.11.5 SWOT Analysis
  • 12.11.6 Key Developments

13. Appendix

• 13.1 About Us